Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -7.84% is 66% above its 5-year average of -22.97%, near the high end of its 5-year range (-71.25%–4.29%).
199.01% below its 12-month average of -2.62%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 4.29%.
EBITDA MARGIN
-7.84%
EBITDA MARGIN AVG TTM
-2.62%
EBITDA MARGIN AVG 3Y
-8.01%
EBITDA MARGIN AVG 5Y
-22.97%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-199.01%
CURRENT VS 3Y AVG
+2.10%
CURRENT VS 5Y AVG
+65.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Strata Critical Medical, Inc.
Market Cap
$412.30M
EBITDA Margin
-7.84%
TTM Avg
-2.62%
3Y Avg
-8.01%
5Y Avg
-22.97%
Market Cap
$411.21M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$417.06M
EBITDA Margin
-189.54%
TTM Avg
-258.01%
3Y Avg
-315.18%
5Y Avg
-540.94%
Market Cap
$406.58M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$405.74M
EBITDA Margin
39.39%
TTM Avg
8.38%
3Y Avg
8.38%
5Y Avg
8.38%
Market Cap
$418.95M
EBITDA Margin
-232.13%
TTM Avg
-495.69%
3Y Avg
-578.57%
5Y Avg
-532.48%
Market Cap
$419.87M
EBITDA Margin
-1867.60%
TTM Avg
-990.65%
3Y Avg
-608.01%
5Y Avg
-2572.38%
Market Cap
$404.24M
EBITDA Margin
-1.71%
TTM Avg
-2.46%
3Y Avg
-6.59%
5Y Avg
-11.17%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Strata Critical Medical, Inc. (SRTA) | $412.30M | -7.84% | -2.62% | -8.01% | -22.97% |
| Rezolute, Inc. (RZLT)vs › | $412.13M | N/A | N/A | N/A | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | N/A | N/A | N/A | N/A |
| Senseonics Holdings, Inc. (SENS)vs › | $417.06M | -189.54% | -258.01% | -315.18% | -540.94% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $406.58M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $405.74M | 39.39% | 8.38% | 8.38% | 8.38% |
| Editas Medicine, Inc. (EDIT)vs › | $418.95M | -232.13% | -495.69% | -578.57% | -532.48% |
| Prothena Corporation plc (PRTA)vs › | $419.87M | -1867.60% | -990.65% | -608.01% | -2572.38% |
| Myriad Genetics, Inc. (MYGN)vs › | $404.24M | -1.71% | -2.46% | -6.59% | -11.17% |
| Neurogene Inc. (NGNE)vs › | $402.17M | -8579.24% | -8579.24% | -8579.24% | -8579.24% |
Gross Margin
20.6%
EBITDA Margin
-7.8%
Operating Margin
-8.0%
Net Margin
15.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 4.29% |
| 2026-03-31 | 0.13% |
| 2025-12-31 | -5.09% |
| 2025-09-30 | -7.95% |
| 2025-06-30 | -4.49% |
| 2025-03-31 | -10.84% |
| 2024-12-31 | -12.59% |
| 2024-09-30 | -3.02% |
| 2024-06-30 | -15.59% |
| 2024-03-31 | -16.06% |
| 2023-12-31 | -71.25% |
| 2023-09-30 | -7.85% |
| 2023-06-30 | -17.05% |
| 2023-03-31 | -25.76% |
| 2022-12-31 | -51.36% |
| 2022-09-30 | -19.80% |
| 2022-06-30 | -24.07% |
| 2022-03-31 | -47.11% |
| 2021-12-31 | -46.95% |
| 2021-09-30 | -39.89% |
| 2021-06-30 | -60.00% |
| 2021-03-31 | -44.20% |
| 2020-12-31 | -27.91% |
| 2020-09-30 | -7.25% |
| 2020-06-30 | -39.06% |
| 2020-03-31 | -49.85% |
| 2019-12-31 | -89.41% |
